Cryoport Past Earnings Performance
Past criteria checks 0/6
Cryoport's earnings have been declining at an average annual rate of -16.5%, while the Life Sciences industry saw earnings growing at 5.5% annually. Revenues have been growing at an average rate of 24.4% per year.
Key information
-16.5%
Earnings growth rate
-13.1%
EPS growth rate
Life Sciences Industry Growth | 21.5% |
Revenue growth rate | 24.4% |
Return on equity | -28.6% |
Net Margin | -53.7% |
Last Earnings Update | 31 Dec 2024 |
Recent past performance updates
Recent updates
Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 06Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Feb 22Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
Dec 03Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Nov 06The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Aug 09Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Jul 22Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch
Jun 25Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
Apr 15Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 15Cryoport Tanks On Chilling Results And Bad Decisions
Mar 14Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Mar 10Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)
Jan 15Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Oct 06Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term
Jul 23Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity
Jul 12Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Jun 13Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 06Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially
Nov 07Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Sep 23Cryoport: A Rare Investing Opportunity
Sep 22Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services
Sep 08Cryoport: Rapid Growth Is Great, But Shares Look Overpriced
Jul 30Cryoport: To Resume Aggressive Growth
May 11Revenue & Expenses Breakdown
How Cryoport makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 24 | 228 | -123 | 148 | 18 |
30 Sep 24 | 226 | -166 | 147 | 18 |
30 Jun 24 | 226 | -181 | 149 | 19 |
31 Mar 24 | 225 | -121 | 146 | 19 |
31 Dec 23 | 233 | -108 | 141 | 18 |
30 Sep 23 | 236 | -55 | 134 | 18 |
30 Jun 23 | 241 | -47 | 128 | 17 |
31 Mar 23 | 248 | -38 | 123 | 16 |
31 Dec 22 | 237 | -45 | 120 | 16 |
30 Sep 22 | 233 | -296 | 109 | 15 |
30 Jun 22 | 230 | -297 | 103 | 15 |
31 Mar 22 | 222 | -293 | 98 | 16 |
31 Dec 21 | 223 | -284 | 98 | 17 |
30 Sep 21 | 215 | -76 | 93 | 16 |
30 Jun 21 | 169 | -78 | 77 | 15 |
31 Mar 21 | 122 | -77 | 61 | 12 |
31 Dec 20 | 79 | -75 | 47 | 9 |
30 Sep 20 | 40 | -22 | 28 | 7 |
30 Jun 20 | 38 | -23 | 36 | 6 |
31 Mar 20 | 37 | -20 | 33 | 5 |
31 Dec 19 | 34 | -18 | 31 | 4 |
30 Sep 19 | 30 | -20 | 31 | 3 |
30 Jun 19 | 26 | -9 | 20 | 2 |
31 Mar 19 | 22 | -9 | 18 | 2 |
31 Dec 18 | 20 | -10 | 17 | 2 |
30 Sep 18 | 17 | -10 | 16 | 2 |
30 Jun 18 | 15 | -9 | 15 | 2 |
31 Mar 18 | 13 | -9 | 14 | 1 |
31 Dec 17 | 12 | -8 | 13 | 1 |
30 Sep 17 | 11 | -10 | 12 | 1 |
30 Jun 17 | 10 | -10 | 11 | 1 |
31 Mar 17 | 9 | -12 | 11 | 1 |
31 Dec 16 | 8 | -13 | 11 | 1 |
30 Sep 16 | 7 | -12 | 11 | 1 |
30 Jun 16 | 6 | -12 | 11 | 1 |
31 Mar 16 | 6 | -15 | 10 | 0 |
31 Dec 15 | 6 | -16 | 9 | 0 |
30 Sep 15 | 5 | -15 | 8 | 0 |
30 Jun 15 | 4 | -16 | 7 | 0 |
31 Mar 15 | 4 | -12 | 6 | 0 |
31 Dec 14 | 4 | -10 | 6 | 0 |
30 Sep 14 | 3 | -10 | 6 | 0 |
30 Jun 14 | 3 | -21 | 5 | 0 |
31 Mar 14 | 3 | -20 | 5 | 0 |
Quality Earnings: CYRX is currently unprofitable.
Growing Profit Margin: CYRX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CYRX is unprofitable, and losses have increased over the past 5 years at a rate of 16.5% per year.
Accelerating Growth: Unable to compare CYRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CYRX is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-3.9%).
Return on Equity
High ROE: CYRX has a negative Return on Equity (-28.55%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/16 18:20 |
End of Day Share Price | 2025/03/14 00:00 |
Earnings | 2024/12/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cryoport, Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Yuan Zhi | B. Riley Securities, Inc. |
Andrew D'Silva | B. Riley Securities, Inc. |
David Larsen | BTIG |